{
    "id": 13020,
    "fullName": "TET2 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "TET2 mutant indicates an unspecified mutation in the TET2 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 54790,
        "geneSymbol": "TET2",
        "terms": [
            "TET2",
            "KIAA1546",
            "MDS"
        ]
    },
    "variant": "mutant",
    "createDate": "10/09/2015",
    "updateDate": "08/26/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6223,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In multiple clinical studies, including a meta-analysis, TET2 mutations were associated with shorter overall survival in patients with acute myeloid leukemia (PMID: 24524305, PMID: 25412851, PMID: 24994606).",
            "molecularProfile": {
                "id": 13182,
                "profileName": "TET2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5481,
                    "pubMedId": 24524305,
                    "title": "Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24524305"
                },
                {
                    "id": 5482,
                    "pubMedId": 25412851,
                    "title": "Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25412851"
                },
                {
                    "id": 5483,
                    "pubMedId": 24994606,
                    "title": "Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24994606"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3330,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, presence of a TET2 mutation correlated with higher overall response rate (ORR) in patients with myelodysplastic syndrome and acute myeloid leukemia following treatment with Vidaza (azacitidine), with an ORR of 85% (11/3) in TET2-mutated patients, compared to 47% (34/47) in patients with wild-type TET2, but did not correlate with overall survival (PMID: 21494260).",
            "molecularProfile": {
                "id": 13182,
                "profileName": "TET2 mutant"
            },
            "therapy": {
                "id": 651,
                "therapyName": "Azacitidine",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3737,
                    "pubMedId": 21494260,
                    "title": "Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21494260"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18955,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "TET2 mutations aid in the diagnosis of angioimmunoblastic T-cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 13182,
                "profileName": "TET2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 111147,
                "name": "angioimmunoblastic T-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6170,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65% vs. 44%; OR 2.37, P=0.49) (PMID: 25224413).",
            "molecularProfile": {
                "id": 22786,
                "profileName": "ASXL1 wild-type TET2 mut"
            },
            "therapy": {
                "id": 650,
                "therapyName": "Decitabine",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3740,
                    "pubMedId": 25224413,
                    "title": "TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25224413"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6169,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65% vs. 44%; OR 2.37, P=0.49) (PMID: 25224413).",
            "molecularProfile": {
                "id": 22786,
                "profileName": "ASXL1 wild-type TET2 mut"
            },
            "therapy": {
                "id": 651,
                "therapyName": "Azacitidine",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3740,
                    "pubMedId": 25224413,
                    "title": "TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25224413"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13182,
            "profileName": "TET2 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13185,
            "profileName": "ASXL1 mut TET2 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22786,
            "profileName": "ASXL1 wild-type TET2 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}